BioAtla (NASDAQ:BCAB) Posts Quarterly Earnings Results

BioAtla (NASDAQ:BCAB) released its quarterly earnings results on Thursday. The company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of ($8.50) by $8.77, FiscalAI reports. The business had revenue of $6.50 million for the quarter.

BioAtla Stock Performance

Shares of NASDAQ:BCAB traded up $0.07 during trading hours on Thursday, hitting $3.45. 148,563 shares of the company’s stock traded hands, compared to its average volume of 49,317. The company’s fifty day simple moving average is $3.65 and its two-hundred day simple moving average is $5.96. The company has a market cap of $5.73 million, a price-to-earnings ratio of -0.08 and a beta of 0.78. BioAtla has a 52 week low of $3.12 and a 52 week high of $71.50.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of BioAtla in a research report on Wednesday, June 3rd. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $200.00.

Institutional Trading of BioAtla

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Woodline Partners LP purchased a new position in BioAtla during the 1st quarter worth approximately $26,000. Jane Street Group LLC raised its stake in BioAtla by 55.4% during the 4th quarter. Jane Street Group LLC now owns 346,774 shares of the company’s stock valued at $197,000 after purchasing an additional 123,597 shares during the period. Vanguard Group Inc. lifted its holdings in shares of BioAtla by 9.1% in the third quarter. Vanguard Group Inc. now owns 1,945,795 shares of the company’s stock valued at $1,339,000 after purchasing an additional 162,647 shares in the last quarter. Susquehanna International Group LLP lifted its holdings in shares of BioAtla by 237.6% in the third quarter. Susquehanna International Group LLP now owns 252,583 shares of the company’s stock valued at $174,000 after purchasing an additional 177,760 shares in the last quarter. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of BioAtla in the fourth quarter worth $104,000. 77.23% of the stock is owned by institutional investors and hedge funds.

About BioAtla

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.